Physician profile
Robert E Goodman
NPI 1235111907
$13,721.62
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,598 · 2020: $1,452 · 2021: $2,060 · 2022: $1,979 · 2023: $2,638 · 2024: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,385 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,385.28 |
| Education | $246.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,050.09 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $1,809.21 | 2019-2024 | |
| Abbvie INC. | $1,254.22 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,231.31 | 2019-2024 | |
| Ucb, INC. | $1,137.55 | 2019-2024 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $882.60 | 2019-2024 | Benlysta |
| Janssen Biotech, INC. | $819.75 | 2019-2024 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $327.63 | 2019-2023 | Taltz |
| Mallinckrodt Hospital Products INC. | $295.65 | 2021-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.71 | 2019-2024 | Cyltezo, Ofev |
| Genzyme Corporation | $226.00 | 2020-2024 | |
| Horizon Therapeutics Plc | $220.98 | 2020-2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $176.93 | 2019-2020 | |
| Genentech USA, INC. | $134.90 | 2019-2024 | Actemra |
| Actelion Pharmaceuticals US, INC. | $110.71 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $94.83 | 2019-2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $78.79 | 2019 | |
| Alnylam Pharmaceuticals INC. | $76.46 | 2019-2023 | Onpattro |
| Astrazeneca Pharmaceuticals Lp | $55.30 | 2022-2024 | Saphnelo |
| Ani Pharmaceuticals, INC. | $50.47 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $40.92 | 2024 | Crysvita |
| Organon LLC | $39.81 | 2023-2024 | Hadlima |
| Aurinia Pharma U.S., INC. | $39.49 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $38.05 | 2024 | |
| Pacira Therapeutics, INC. | $36.72 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.82 | 2022 | |
| Sobi, INC | $20.50 | 2019 | |
| Dermavant Sciences, INC. | $17.73 | 2023 | Vtama |
| Hikma Pharmaceuticals USA | $16.36 | 2021 | |
| Avion Pharmaceuticals | $14.70 | 2020 | |
| Sandoz INC. | $14.59 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $14.58 | 2023 | Idacio |
| Arbor Pharmaceuticals, INC. | $11.86 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.